WindMIL Therapeutics develops cell therapies that utilize insights from bone marrow immunology to target and eliminate cancer cells. Their approach addresses the need for effective treatments in patients with hematologic malignancies, improving survival rates and quality of life.
Funding
$45.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments for hematologic malignancies often fail to provide long-term remission, and many patients lack effective options, leading to poor survival rates and diminished quality of life. The limitations of existing therapies highlight the need for novel approaches that can specifically target and eliminate cancer cells while minimizing damage to healthy tissues.
Solution
WindMIL Therapeutics is developing cell-based immunotherapies derived from a patient's own bone marrow to combat hematologic cancers. This approach leverages the unique properties of bone marrow-resident immune cells to recognize and destroy malignant cells. By harnessing the body's natural defenses, WindMIL aims to create personalized treatments that offer durable responses and improved outcomes for patients with leukemia, lymphoma, and multiple myeloma. The company's technology seeks to overcome the limitations of traditional therapies by providing a targeted and effective means of eliminating cancer cells.
Target Audience
The primary target audience includes patients with hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma, who have relapsed or are refractory to standard treatments.
Features
- Utilizes bone marrow-derived lymphocytes to target hematologic malignancies
- Employs a personalized approach, using a patient's own immune cells
- Seeks to induce durable remissions by specifically eliminating cancer cells
- Aims to improve patient outcomes and quality of life